Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1357923-33-1 | MDL No. : | MFCD22199153 |
Formula : | C6H14ClNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZDTIEZKFOLVALT-UHFFFAOYSA-N |
M.W : | 151.63 | Pubchem ID : | 53249203 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 43.72 |
TPSA : | 32.26 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.83 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.56 |
Log Po/w (WLOGP) : | 0.4 |
Log Po/w (MLOGP) : | 0.57 |
Log Po/w (SILICOS-IT) : | 0.63 |
Consensus Log Po/w : | 0.43 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.07 |
Solubility : | 13.0 mg/ml ; 0.0857 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.81 |
Solubility : | 23.5 mg/ml ; 0.155 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.72 |
Solubility : | 28.7 mg/ml ; 0.189 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71.8% | With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; | Step B: 2-(Azetidin-3-yl)propan-2-ol hydrochloride. To a solution of tert-butyl 3-(2-hydroxypropan-2-yl)azetidine-l-carboxylate (0.87 g, 4.04 mmol) in DCM (15 mL) at 0°C was added 4 M HC1 in dioxane (8.08 mL, 16.16 mmol) dropwise. The reaction was stirred overnight at RT. The reaction mixture was concentrated and dried in vacuo to generate 2-(azetidin-3-yl)propan-2-ol hydrochloride as a brown solid (0.44 g, 71.8 percent yield). |
[ 1185293-84-8 ]
3-Methylpiperidin-4-ol hydrochloride
Similarity: 0.82
[ 240401-25-6 ]
4-(Hydroxymethyl)piperidin-4-ol hydrochloride
Similarity: 0.77
[ 921592-91-8 ]
3-Methylpyrrolidin-3-ol hydrochloride
Similarity: 0.77
[ 928038-44-2 ]
Azetidin-3-ylmethanol hydrochloride
Similarity: 0.76
[ 1185293-84-8 ]
3-Methylpiperidin-4-ol hydrochloride
Similarity: 0.82
[ 240401-25-6 ]
4-(Hydroxymethyl)piperidin-4-ol hydrochloride
Similarity: 0.77
[ 921592-91-8 ]
3-Methylpyrrolidin-3-ol hydrochloride
Similarity: 0.77
[ 928038-44-2 ]
Azetidin-3-ylmethanol hydrochloride
Similarity: 0.76
[ 928038-44-2 ]
Azetidin-3-ylmethanol hydrochloride
Similarity: 0.76
[ 1630907-10-6 ]
2-Azaspiro[3.3]heptan-6-ol hydrochloride
Similarity: 0.76
[ 942308-06-7 ]
3-(Methoxymethyl)azetidine hydrochloride
Similarity: 0.68
[ 124668-46-8 ]
3-Methylazetidin-3-ol hydrochloride
Similarity: 0.68
[ 1417633-09-0 ]
7-Oxa-2-azaspiro[3.5]nonane hydrochloride
Similarity: 0.61